Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR2 | P30518 | 20/20 | 0.75 |
| ▸ | AVPR1A | P37288 | 15/20 | 0.75 |
| ▸ | OXTR | P30559 | 2/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lixivaptan SCHEMBL29377065 | 0.86 | AVPR2 (1.00) | AVPR2AVPR1AOXTR | |
| Lixivaptan SCHEMBL1649340 | 0.86 | AVPR2 (1.00) | AVPR2AVPR1AOXTR | |
| Lixivaptan SCHEMBL29373157 | 0.86 | AVPR2 (1.00) | AVPR2AVPR1AOXTR | |
| Lixivaptan SCHEMBL29387791 | 0.86 | AVPR2 (1.00) | AVPR2AVPR1AOXTR | |
| SCHEMBL6623964 | 0.84 | AVPR2 (0.82) | AVPR2AVPR1AOXTR | |
| SCHEMBL8317010 | 0.83 | AVPR2 (0.75) | AVPR2AVPR1AOXTR | |
| SCHEMBL8313381 | 0.83 | AVPR2 (1.00) | AVPR2AVPR1AOXTR | |
| SCHEMBL7341103 | 0.81 | AVPR2 (0.90) | AVPR2AVPR1AOXTR | |
| SCHEMBL7339573 | 0.79 | AVPR2 (1.00) | AVPR2AVPR1AOXTR | |
| SCHEMBL7332865 | 0.79 | AVPR2 (1.00) | AVPR2AVPR1AOXTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8946224-B2 | Substituted [1,2,4]triazolo[4,3-A]pyrazines for medicaments and pharmaceutical compositions | REDX PHARMA LIMITED (GB) | 2015-02-03 | — | — | US | disclosed |
| US-8946224-B2 | Substituted [1,2,4]triazolo[4,3-A]pyrazines for medicaments and pharmaceutical compositions | REDX PHARMA LIMITED (GB) | 2015-02-03 | — | — | US | disclosed |
| US-8946224-B2 | Substituted [1,2,4]triazolo[4,3-A]pyrazines for medicaments and pharmaceutical compositions | REDX PHARMA LIMITED (GB) | 2015-02-03 | — | — | US | disclosed |
| EP-2638007-A2 | DRUG DERIVATIVES | Redx Pharma Limited (GB) | 2013-09-18 | — | — | EP | disclosed |
| US-20130225594-A1 | DRUG DERIVATIVES | REDX PHARMA PLC (GB) | 2013-08-29 | — | — | US | disclosed |
| US-20130225594-A1 | DRUG DERIVATIVES | REDX PHARMA PLC (GB) | 2013-08-29 | — | — | US | disclosed |
| US-20130225594-A1 | DRUG DERIVATIVES | REDX PHARMA PLC (GB) | 2013-08-29 | — | — | US | disclosed |
| WO-2012063085-A2 | DRUG DERIVATIVES | REDX PHARMA LIMITED (GB) | 2012-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225594-A1 | DRUG DERIVATIVES | SQOR, NQO1, CYP2D6 | AVPR2 2003/4885AVPR1A 2491/4885OXTR 506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.